Literature DB >> 7930593

CD4+CD8- T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse.

P J Blair1, S J Bultman, J C Haas, B T Rouse, J E Wilkinson, V L Godfrey.   

Abstract

Mice hemizygous for the X-linked mutation, scurfy (sf), exhibit a fatal lymphoreticular disease that is mediated by T lymphocytes. To evaluate the respective roles of CD4 or CD8 single positive T cells in scurfy disease, neonates were treated with mAbs directed against the CD4 or CD8 molecules. Whereas mice treated with an anti-CD8 Ab developed lesions and succumbed to disease at the same time (17 days) as their untreated scurfy littermates, mice treated with an anti-CD4 Ab lived up to 11 wk before developing scurfy disease. To insure a more complete elimination of the T cell subsets, the scurfy mutation was bred onto beta 2-microglobulin (beta 2m)-deficient (CD8-less) and CD4-deficient transgenic mouse lines. Whereas there was little moderation of disease in beta 2m-deficient scurfy mice, CD4-deficient scurfy mice had markedly decreased scurfy lesions and a prolonged life span, similar to that of anti-CD4-treated sf/Y mice. Additionally, scurfy disease was transplanted into H-2-compatible nude mice through the adoptive transfer of CD4+CD8- T cells, but not CD4-CD8+ T cells. Flow-cytometric analysis revealed that sf/Y mice have an increased percentage of activated CD4+ T cells in their lymph nodes. In addition, there is an increase in the in vitro production of cytokines in the cultured splenocytes of CD8-less, but not CD4-less, scurfy mice. These data suggest that CD4+ T cells are critical mediators of disease in the scurfy mouse.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930593

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

Review 1.  Genetic control of the inflammatory T-cell response in regulatory T-cell deficient scurfy mice.

Authors:  Rahul Sharma; Shyr-Te Ju
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

2.  Prospective immunological profiling in a case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX).

Authors:  A C Bakke; M Z Purtzer; R S Wildin
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

3.  Escape from tolerance in the human X-linked autoimmunity-allergic disregulation syndrome and the Scurfy mouse.

Authors:  D D Patel
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

4.  Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3.

Authors:  Jeremy A Goettel; Subhabrata Biswas; Willem S Lexmond; Ada Yeste; Laura Passerini; Bonny Patel; Siyoung Yang; Jiusong Sun; Jodie Ouahed; Dror S Shouval; Katelyn J McCann; Bruce H Horwitz; Diane Mathis; Edgar L Milford; Luigi D Notarangelo; Maria-Grazia Roncarolo; Edda Fiebiger; Wayne A Marasco; Rosa Bacchetta; Francisco J Quintana; Sung-Yun Pai; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 5.  Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications.

Authors:  Lequn Li; Vassiliki A Boussiotis
Journal:  J Mol Med (Berl)       Date:  2006-09-14       Impact factor: 4.599

Review 6.  CD4+ Tregs and immune control.

Authors:  Zoltán Fehérvari; Shimon Sakaguchi
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

7.  Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells.

Authors:  Estelle Bettelli; Maryam Dastrange; Mohamed Oukka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-24       Impact factor: 11.205

Review 8.  Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.

Authors:  R S Wildin; S Smyk-Pearson; A H Filipovich
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

9.  Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.

Authors:  Anna Cline-Smith; Jesse Gibbs; Elena Shashkova; Zachary S Buchwald; Deborah V Novack; Rajeev Aurora
Journal:  JCI Insight       Date:  2016-08-18

10.  Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes.

Authors:  S K Smyk-Pearson; A C Bakke; P K Held; R S Wildin
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.